Is the HScore useful in COVID-19?

被引：28

作者：

Leverenz, David L. ^{[1
]}

Tarrant, Teresa K. ^{[1
]}

机构：

[1] Duke Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Durham, NC 27710 USA

来源：

LANCET | 2020年 / 395卷 / 10236期

关键词：

D O I：

10.1016/S0140-6736(20)31057-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E83 / E83

页数：1

共 4 条

[1]

Chen G., 2020, J CLIN INVEST, DOI [DOI 10.1172/JCI137244, 10.1172/JCI137244]

[2] Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome [J].

Fardet, Laurence ;

Galicier, Lionel ;

Lambotte, Olivier ;

Marzac, Christophe ;

Aumont, Cedric ;

Chahwan, Doumit ;

Coppo, Paul ;

Hejblum, Gilles .

ARTHRITIS & RHEUMATOLOGY, 2014, 66 (09) :2613-2620

[3] COVID-19: consider cytokine storm syndromes and immunosuppression [J].

Mehta, Puja ;

McAuley, Daniel F. ;

Brown, Michael ;

Sanchez, Emilie ;

Tattersall, Rachel S. ;

Manson, Jessica J. .

LANCET, 2020, 395 (10229) :1033-1034

[4] Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [J].

Zhou, Fei ;

Yu, Ting ;

Du, Ronghui ;

Fan, Guohui ;

Liu, Ying ;

Liu, Zhibo ;

Xiang, Jie ;

Wang, Yeming ;

Song, Bin ;

Gu, Xiaoying ;

Guan, Lulu ;

Wei, Yuan ;

Li, Hui ;

Wu, Xudong ;

Xu, Jiuyang ;

Tu, Shengjin ;

Zhang, Yi ;

Chen, Hua ;

Cao, Bin .

LANCET, 2020, 395 (10229) :1054-1062

← 1 →